Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6524-8. doi: 10.1016/j.bmcl.2009.10.054. Epub 2009 Oct 24.

Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.

Author information

1
Department of Cancer Chemistry, AstraZeneca R&D Boston, Waltham, MA 02451, USA. Stephanos.Ioannidis@astrazeneca.com

Abstract

The design, synthesis and biological evaluation of a series of pyrazol-3-ylamino pyrazines as potent and selective JAK2 kinase inhibitors is reported, along with the pharmacokinetic and pharmacodynamic properties of lead compounds.

PMID:
19857966
DOI:
10.1016/j.bmcl.2009.10.054
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center